From anti-infective research to cancer therapeutics, AMS BioteQ leverages proprietary novel compound design and rapid synthesis capabilities to build a small molecule drug discovery platform and pipeline spanning antibacterial, antiviral, and anticancer applications.
The World Health Organization (WHO) has warned that antimicrobial resistance (AMR) could become one of the leading causes of death by 2050 if left unaddressed. At the same time, emerging infectious diseases such as COVID-19, dengue fever, and H5N1 continue to threaten global public health systems. In oncology, the global cancer therapeutics market reached USD 223 billion in 2024, with Antibody-Drug Conjugates (ADCs) recognized as one of the fastest-growing therapeutic modalities.
AMS BioteQ's R&D Capabilities
AMS BioteQ's small molecule drug discovery platform originated from the company’s long-term focus on antimicrobial resistance research. Leveraging expertise in natural product extraction, chemical synthesis, and drug development, we have established:
・A proprietary novel compound library
・Rapid compound synthesis capabilities within 3–6 months
・Comprehensive experience in animal study design and preclinical development
・A collaborative preclinical research network with domestic and international academic, research, and medical institutions
【FORMOSA-1117｜Antibacterial Drug Candidate】
・Mechanism of Action: Inhibits DNA polymerase and gyrase activity, disrupting bacterial biofilm formation
・Target Indications: Multidrug-resistant strains including MRSA, VRE, VISA, hVISA, CR-EC, and CR-KP
・Molecular Profile: Small-molecule natural benzene-ring compound (molecular weight: 182.2 g/mol) with strong absorption potential
・Preclinical Validation: Validated by Chi Mei Medical Center
・Development Status: Chemical synthesis completed; advancing toward animal toxicity studies and efficacy validation
【YUAN-03｜Antiviral Drug Candidate】
・Target Indications: Human coronavirus hCoV-OC43, SARS-CoV-2, and related variants
・Preclinical Validation: Validated by National Health Research Institutes (NHRI) and National Taiwan University Hospital, demonstrating nearly 100% in vitro inhibition at specific effective doses
・Development Status: Total synthesis completed; preparing for animal toxicity studies and efficacy validation
【AMS-2140｜Broad-Spectrum Antiviral Drug Candidate】
・Mechanism of Action: Potentially targets viral non-structural proteins NS1–NS5
・Target Indications: Emerging viral diseases including dengue virus and H5N1 avian influenza
・Preclinical Validation: Jointly validated by Chulalongkorn University, Mahidol University Siriraj Hospital, National Cheng Kung University, Kaohsiung Medical University, and Chi Mei Medical Center
・Development Status: Currently undergoing animal toxicity studies and efficacy validation
【TenTacle™｜ADC Linker-Conjugate Compound】
・Technology Positioning: Core linker technology targeting the global ADC (Antibody-Drug Conjugate) oncology market
・Strategic Significance: Linkers are critical determinants of ADC stability, therapeutic efficacy, and safety
・Recent Milestone: Taiwan invention patent granted in April 2026